BioNTech's experimental cancer treatment BNT113, combined with pembrolizumab, failed to show a significant improvement in progression-free survival in its Phase 2/3 AHEAD-MERIT trial. Despite missing this first primary endpoint, the trial will proceed to evaluate overall survival, which could still lead to a positive outcome. Following the update, BioNTech's shares dropped about 5.5%, though Citi maintained a Buy rating and $125 price target, signaling ongoing confidence in the drug's potential. The trial involves patients with advanced HPV16-positive head and neck cancer, and BioNTech remains blinded to ongoing data.
Following the news about BioNTech's BNT113 trial results, the company's shares have declined on Pluang. As of Oct 13, 2026 23:31 WIB, BioNTech SE (BNTX) trades at USD 90.13, down 5.96% for the day, with a market cap of $24.08 billion. The stock remains below its 52-week high of $119.34 but above its 52-week low of $83.89, reflecting ongoing market adjustments to the trial update.
BioNTech announced that its Phase 2/3 trial of mRNA cancer immunotherapy BNT113 combined with pembrolizumab did not meet the first primary endpoint of progression-free survival in treating HPV16-positive head and neck cancer. However, the trial will ...
Moderna's stock rose 5% following its addition to the NASDAQ 100, driven by automatic fund buying linked to the index inclusion. This marks a shift from its COVID-19 vaccine identity to a growth biotech with a promising oncology pipeline, highlighted...
